 
 
 
SPARC/Sec/SE/2025-26/40 November 20, 2025 
 
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051. 
 
Scrip Symbol: SPARC 
BSE Limited,  
Market Operations Dept. 
P. J. Towers,  
Dalal Street,   
Mumbai - 400 001. 
 
Scrip Code: 532872 
 
Dear Sir/Madam, 
 
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure 
Requirements) Regulations, 2015 – Press Release 
 
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) 
Regulations, 2015, we enclose herewith the Press Release about “Complete Response 
Letter Resubmission for PDP-716 NDA by Ocuvex”, which we shall be released after this 
intimation. 
 
This is for your information and dissemination. 
 
 
For Sun Pharma Advanced Research Company Ltd.  
 
 
Kajal Damania 
Company Secretary and Compliance Officer 
 
Encl: As above 
 
 
   
 
                                          
  
 
 
 
FOR IMMEDIATE RELEASE 
SPARC announces Complete Response Letter Resubmission 
for PDP-716 NDA by Ocuvex  
 
Mumbai, India, November 20, 2025 – Sun Pharma Adva nced Research Company Ltd. 
(Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872, “SPARC”) today 
announced Complete Response Letter (CRL)  resubmission to the US Food and Drug 
Administration (FDA) by Ocuvex Therapeutics Inc. ( Ocuvex) for the PDP-716 New Drug 
Application (NDA). 
The PDP-716 Complete Response resubmission addresses the FDA CRL issued in July 2023 , 
stating unresolved facility inspection -related conditions at a third -party Active Pharmaceutical 
Ingredient (API) manufacturing facility. The FDA did not raise any concerns related to the efficacy 
or safety of PDP-716. 
SPARC will provide an update after the FDA has determined that the response resubmission is 
complete. 
 
About PDP-716: 
PDP-716 is a novel, once daily, ophthalmic suspension of brimonidine tartrate 0.35%. PDP -716 was 
developed using SPARC’s proprietary TearActTM technology.  
 
About Sun Pharma Advanced Research Company Ltd. (CIN - L73100GJ2006PLC047837): 
Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio -pharmaceutical company 
focused on continuously improving standards of care for patients globally, through innovation in 
therapeutics and delivery. SPARC aims to advance availability of treatment options for patients across the 
world. More information about the company can be found at www.sparc.life 
 
Disclaimer: 
Statements in this “Document” describing the Company’s objectiv es, projections, estimates, expectations, plans or 
predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable 
securities laws and regulations. Actual results, performance or achievements could differ m aterially from those 
expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect 
developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances 
after the date hereof. 
Contact 
Jaydeep Issrani 
Tel +91 22 66455645, Ext: 5787 
Tel Direct +91 22 6645 5787 
Mobile +91-9820216916 
E-mail jaydeep.issrani@sparcmail.com 
